Trials / Unknown
UnknownNCT03814447
The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer
The Clinical Research of Fourth Generation CART-cell Therapy in Refractory-Relapsed Ovarian Cancer
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Shanghai 6th People's Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to study the safety and feasibility of anti- Mesothelin Chimeric Antigen Receptor T-Cell (MESO CAR-T cells) therapy for Refractory-Relapsed Ovarian Cancer
Detailed description
Primary Objectives: 1\. To determine the safety and feasibility of anti- MESO CAR-T cells therapy for Refractory-Relapsed Ovarian Cancer Secondary Objectives: 1. To access the efficacy of anti- MESO CAR-T cells in patients with ovarian cancer. 2. To determine in vivo dynamics and persistency of anti- MESO CAR-T cells 3. To assess the quality of life in patients with ovarian cancer after treatment with anti- MESO CAR-T cells.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | anti- MESO CAR-T cells | Autologous genetically modified anti- MESO CAR transduced T cells |
| DRUG | Fludarabine | Dose: 30mg/m2/d |
| DRUG | Cyclophosphamide | Dose: 300mg/m2/d |
Timeline
- Start date
- 2019-08-16
- Primary completion
- 2023-01-01
- Completion
- 2023-01-01
- First posted
- 2019-01-24
- Last updated
- 2021-08-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03814447. Inclusion in this directory is not an endorsement.